‘Global Radiopharmaceutical Market Worth Over $5 Billion In 2017’ Says Visiongain Report

16 August 2017
Pharma

Visiongain’s new report The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography indicates that the global Radiopharmaceutical market will see over $5bn in revenue in 2017.
The lead analyst of the report said:

“The market for radiopharmaceuticals is mainly driven by factors such as growth in R&D investments made in the biotechnology and pharmaceutical sector, technological advancements in nuclear medicine, the increasing burden of cancer and the ageing global population. The application of radiopharmaceuticals in diverse range of medical conditions will provide new growth opportunities to key players in the radiopharmaceutical market.

The competitive landscape of the global biosimulation market experiences intense competition to expand their share across globe. The Key players in the global biosimulation market include Siemens AG, Eckert & Ziegler, Lantheus Medical Imaging, Cardinal Health, Inc. and Bayer AG.
Technological advancements coupled with focus of key players focused on emerging nations to capitalize on their potential is expected to propel the growth of the global radiopharmaceutical market during the forecast period.”

The 234-page report contains 193 tables, charts and graphs that add visual analysis in order to explain developing trends within the Radiopharmaceutical market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Radiopharmaceutical submarkets. The market for radiopharmaceuticals is segmented based on application, radioisotope, source, end-user, and by geography. Based on application, the radiopharmaceutical market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology and Others. Based on radioisotope, the radiopharmaceutical market is segmented into Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111 and others. The radiopharmaceutical market by source market is segmented into cyclotrons and nuclear reactors. Based on the end-user the market is categorized into hospitals, diagnostic imaging centres, ambulatory surgical centres and cancer research institutes. The geographical breakdown includes analysis of North America, Latin America. Western Europe, Eastern Europe, Asia-Pacific, and MEA.

The 234-page report offers market forecasts and analysis for 6 regional and 21 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering
9 companies leading the Radiopharmaceutical field in detail.

The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography report will be of value to anyone who wants to better understand the radiopharmaceutical market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the radiopharmaceutical industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever